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The mammalian target of rapamycin (mTOR) is a central
regulator of cell growth and proliferation. mTOR signaling
is frequently dysregulated in oncogenic cells, and thus an
attractive target for anticancer therapy. Using CellDesigner,
a modeling support software for graphical notation, we
presenthereinacomprehensivemapofthemTORsignaling
network, which includes 964 species connected by 777
reactions. The map complies with both the systems biology
markup language (SBML) and graphical notation (SBGN)
for computational analysis and graphical representation,
respectively. As captured in the mTOR map, we review and
discuss our current understanding of the mTOR signaling
network and highlight the impact of mTOR feedback and
crosstalk regulations on drug-based cancer therapy. This
map is available on the Payao platform, a Web 2.0 based
community-wide interactive process for creating more accu-
rate and information-rich databases. Thus, this comprehen-
s i v em a po ft h em T O Rn e t w o r kw i l ls e r v ea sat o o lt of a c i l i t a t e
systems-level study of up-to-date mTOR network components
and signaling events toward the discovery of novel regulatory
processes and therapeutic strategies for cancer.
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Introduction
The tale of the drug rapamycin and its functional target TOR
(target of rapamycin) has attracted monumental scientiﬁc and
clinicalinterestoverthepastfewdecades.Rapamycinwasﬁrst
identiﬁed as a potent antifungal metabolite produced by
Streptomyces hygroscopicus (Vezina et al, 1975), a bacterial
strain originally isolated from a soil sample collected on Easter
Island in the South Paciﬁc. Surprisingly, rapamycin was
subsequently found to possess immunosuppressive and
antitumorigenic properties (Chiang and Abraham, 2007;
Guertin and Sabatini, 2007). The mode of action of rapamycin
involves its interaction with the immunophilin FKbinding
protein–12 (FKBP12; Harding et al, 1989). Studies in budding
yeast determined that an FKBP12–rapamycin complex
directly inhibits a B290kDa Ser/Thr kinase termed ‘target of
rapamycin’ (TOR) (Heitman et al, 1991). Subsequently,
the mammalian ortholog of TOR was identiﬁed and termed
FKBP–rapamycin-associated protein (FRAP) and rapamycin
and FKBP12 target (RAFT) (Brown et al, 1994; Sabatini et al,
1994), and is commonly referred to as mammalian TOR
(mTOR). In the last two decades, scientists have used
rapamycin to decipher mTOR’s complex biological functions,
which include the regulation of cell growth, proliferation and
survivalinresponsetonutrients,growthfactorsandhormones
(Corradetti and Guan, 2006; Wullschleger et al, 2006; Foster
and Fingar, 2010). mTOR has also attracted broad interest
because of its involvement inmanyhuman diseases, including
type II diabetes and several types of cancer (Efeyan and
Sabatini, 2010). These observations have guided the develop-
ment of additional mTOR inhibiting drugs (rapalogs and
second-generation inhibitors), many of which are currently
being evaluated for their therapeutic efﬁcacy (Easton and
Houghton, 2006).
Over the past few years, intense efforts have revealed many
new mTOR regulatory proteins across a complex network of
positive and negative regulatory mechanisms (Dunlop and
Tee, 2009;Efeyan and Sabatini, 2010). Thisincreasedcomplex-
ity impacts our ability to interpret and predict the regulation of
the mTOR network, which is essential to better understand
mTOR-related diseases. To unravel this complexity, computa-
tional approaches combined with mathematical modeling
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2008). To this end, a crucial task involves the reconstruction
of networks in a biologically meaningful manner by manual
curation from literature or automated curation from pathway
databases (Adriaens et al, 2008; Bauer-Mehren et al,
2009). Some of these databases represent pathways in
computer-readable standard formats, such as biological
pathway exchange (BioPAX; www.biopax.org) and systems
biology markup language (SBML; Hucka et al, 2003),
allowing exchange between different software platforms and
further processing by network analysis, visualization and
modeling tools. However, a recent evaluation conducted to
determine the accuracy and completeness of current pathway
databases concluded that manual intervention is still needed
to obtain a comprehensive and accurate view of a particular
signaling network (Bauer-Mehren et al, 2009). Furthermore,
manual reconstruction of such networks has been shown to be
crucial in analyzing and interpreting structural features and
global properties of signaling pathways (Oda et al, 2005;
Kitano and Oda, 2006; Oda and Kitano, 2006; Calzone et al,
2008).
On the basis of the current scientiﬁc and clinical interest in
understanding the precise regulation and function of mTOR,
we set out to communicate the mTOR network in both human-
and computer-readable formats. Using CellDesigner (http://
celldesigner.org), a modeling support software (Funahashi
et al, 2007), we present a manually assembled map of the
mTOR signaling network. This map complies with SBML and
the systems biology graphical notation (SBGN) process
diagram (Kitano et al, 2005;LeNovereet al, 2009) for machine
readableandgraphicalrepresentation,respectively.Despiteits
static nature, a comprehensive map of molecular interactions
would serve as a valuable working model to gain a systems-
level understanding of the mTOR network. The map would
also serve as a useful reference, and greatly help research on
mTOR signaling. In this regard, we have reviewed our current
understanding of the mTOR signaling network and discuss its
particular relevance to cancer therapy. In addition, we
elaborate on future directions to ensure a community-based
effort in updating the mTOR network accurately through
concurrent interventions.
Graphical notations for network
representation
Standardizing the visual representation is crucial for more
efﬁcient and accurate transmission of biological knowledge
between different communities. Recently, a group of bioche-
mists, modelers and computerscientists proposed the SBGN, a
visual convention for graphical representation of biological
networks (Le Novere et al, 2009; www.sbgn.org). The SBGN
aims at standardizing a systematic and unambiguous graphi-
cal notation and enables software tool support for computa-
tional analysis. SBGN deﬁnes three complementary types of
visual languages: (1) process diagram, (2) entity relationship
diagram and (3) activity ﬂow diagram. In order to stimulate
implementation of SBGN support and the use of the notation,
the symbols used to represent molecules and interactions
related to the mTOR signaling network are based on the
process diagram (Figures 2 and 3) and the activity ﬂow
diagram (Figure 4).
Process diagram
In Figure 1A, the process diagram is exempliﬁed with the
TSC1–TSC2 complex, a critical negative regulator of the
rapamycin-sensitive mTOR complex-1 (mTORC1). In this
diagram, the multiple phosphorylation states of TSC1–TSC2
are represented in a system of active or inactive transitive
nodes. Using the unphosphorylated form as the initial node,
we show that the TSC1–TSC2 complex is phosphorylated,
altering its ability to act as a GAP toward Rheb in vivo. More
precisely, the catalysis arrows showthat the transition of TSC2
from an active to an inactive state is mediated by the protein
kinases AKT, ERK1/2, RSK1/2, IKKb and CDK1, whereas
AMPK and GSK3 (glycogen synthase kinase-3) positively
regulateTSC1–TSC2function.Inaddition,theprocessdiagram
language used to illustrate the mTOR signaling network was
created using the CellDesigner software, which enables users
to store data for each molecule and reaction in the protein and
reaction notes, respectively. Moreover, the CellDesigner soft-
ware allows users to access references that are used for
individual reaction using PubMed ID (Figure 1). For the
purposeofthisreview,weusedtheprocessdiagramlanguageto
draw the comprehensive mTOR network map (Figure 2) and to
describe upstream regulators of mTORC1 signaling (Figure 3).
Activity ﬂow diagram
The activity ﬂow diagram language is essentially similar to
traditional notation used bymolecularbiologists in thecurrent
literature.Itdepictstheﬂowofinformationbetweenbiochemi-
cal entities in a network and it omits information about the
state transitions of entities. As exempliﬁed in Figure 1B,
activity ﬂow diagrams show only inﬂuences such as ‘activa-
tion’ or ‘inhibition’ of the TSC1–TSC2 complex by different
protein kinases. By ignoring biochemical details of processes
in a network, the number of nodes in an activity ﬂow diagram
is greatly reduced compared with an equivalent process
diagram. In Figure 4, the activity ﬂow diagram has been used
to represent a simpliﬁed version of the mTOR map based on
key factors of the mTOR signaling network.
General characteristics of the mTOR map
In Figure 2, we present a comprehensive map of the mTOR
signaling network that was manually assembled based on the
published literature. To facilitate map exploration, it was
organized in different functional modules, including regula-
tion of mTORC1 and mTORC2, hypoxia, energy content,
growth factor, nutrient, Wnt and TNF signaling, ribosome
and rRNA biogenesis, cap-dependent translation, autophagy,
protein folding, mitochondrial metabolism, cytoskeleton
dynamics, transcription and cell cycle. The map was created
using CellDesigner 4.0.1 (http://celldesigner.org/), a model-
ing software tool that enable users to describe molecular
interactions using the process diagram language, as described
above. Also, the map complies with the SBML, a standard
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et al, 2003).
The map comprises 964 species and 777 reactions.‘Species’
are deﬁned in SBML as ‘an entity that takes part in reactions’
and it is used to distinguish the different states that are caused
by enzymatic modiﬁcation, association, dissociation and
translocation. In the comprehensive mTOR map, species were
categorized as follows: 380 proteins (241 unique proteins),
319complexes, 20 simplemolecules,80genes,87RNA,2ions,
24 degraded products, 6 unknown molecules and 46 pheno-
types. Among all species, 602 were located in the cytoplasm
and at the plasma membrane, 298 in the nucleus, 22 in
endomembranes, 17 in the mitochondria, 12 in Rab7 vesicular
structure, 6 in the extracellular environment, 4 at the
centrosome and 3 in the ER–golgi network. The reactions were
categorized as follows: 210 heterodimer associations, 251 state
transitions, 224 known transitions omitted, 43 dissociations, 32
transportsand17unknowntransitions.Thecriteriaforinclusion
into the map are similar to those for the previously described
maps of the epidermal growth factor receptor (EGFR) and Toll-
like receptor (TLR; Oda et al, 2005; Oda and Kitano, 2006). The
map was manually constructed based on 522 publications
available in the Supplementary information section. This
approach provides better quality in terms of coverage over
major pathway and protein–protein interaction (PPI) databases
(Supplementary Table S2; Bauer-Mehren et al, 2009). As
illustrated in Figure 1, users can directly access references for
individual reaction represented in the map.
PMID: 18508509
RSK1 (human) phosphorylation 
sites: S221, T359, S363, S380, 
T573, S732
PMID: 15342917
Cell line: HEK293
Reaction notes (RSK1/2):
Protein notes (RSK1/2):
Inhibition
Activation
t
u
State transition
Catalysis
Complex
Residue
Legend : A 
Legend :  B
Legends
Activated
protein
Protein
TSC1
TSC2 S1337
T1462
S981
S1798
S1345
S511
S487
S1047
S664
CDK1 AMPK GSK3
AKT ERK1/2 RSK1/2
S939
S417
S1341
P P
P
P
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC1
S511
S487
S1047
S417 TSC1
S511
S487
S1047
S417
TSC1
S511
S487
S1047
S417
TSC1
S511
S487
S1047
S417
TSC1
S511
S487
S1047
S417
TSC1
S511
S487
S1047
S417
TSC1
S511
S487
S1047
S417
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
TSC2
S1345
S1337
S981
S1798
S939 S1341
T1462 S664
P
P
P
P
P
P
P P
P P
IKKβ
Protein
T1462
P
Protein
A
B
GSK3 CDK1 AMPK IKKβ AKT ERK1/2 RSK1/2
TSC1
TSC2
S584 S584 S584 S584
S584 S584 S584 S584
Figure 1 Graphical notations adopted by CellDesigner to illustrate the mTOR signaling network. (A) Process diagrams, explicitly displaying different phosphorylated
forms of the TSC1–TSC2 complex, as well as the processes of phosphorylation on different serine and threonine residues by AKT, ERK1/2, RSK1/2, CDK1, AMPK,
GSK3 and IKKb. The active state of the molecule is indicated by a dashed line surrounding the molecule. Phosphorylation state of the component is represented with
target residues and positions. For individual proteins and reactions, speciﬁc notes such as PubMed ID (PMID) were added, enabling a direct link to the relevant
references. (B) Activity ﬂow diagrams depicting the activation and inhibition of the TSC1–TSC2 complex by the enzymes illustrated in A. In this diagram language, the
biochemical details are omitted.
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in the mTOR signaling network and to identify potential
modulators, we constructed an mTOR protein interaction
network(PIN) froma setof 85 centralmTOR pathway proteins
and physical interaction data from multiple protein interaction
databases using APID2NET (Hernandez-Toro et al, 2007;
Supplementary Figure S1). In the PIN, we identiﬁed 317
additional proteins not present in the current version of the
mTOR map. Thus, integration of proteins and reactions from
the curated mTOR signaling network and the constructed PIN
from public databases offers opportunities to formulate and
test new hypotheses. These are essential if we wish to expand
the current mTOR map and continuously beneﬁt to the
community.
Description of the mTOR signaling
network
In the following section, we review and highlight our current
knowledge of the mechanisms regulating the mTOR signaling
network, as captured in the comprehensive mTOR map
(Figure 2). As mentioned earlier, the comprehensive map
wasorganizedinfunctionalmodulesandincludesannotations
for the speciﬁc reactions and molecular species (PubMed ID of
the relevant literature, outlinks to gene and protein databases,
etc) to facilitate navigation by researchers.
Upstream regulators of mTORC1 signaling
mTORC1 is a rapamycin-sensitive multi-protein complex that
contains mTOR, Raptor and mLST8 (also known as GbL;
mTORC1 module in Figure 2) (Wullschleger et al, 2006;
Bhaskar and Hay, 2007). Other proteins have been shown to
be part of mTORC1, including FKBP38, PRAS40 and Deptor
(LaplanteandSabatini,2009).Mostrecentstudiesalsosuggest
that Raptor binds to PRAS40 (Sancak et al, 2007; Yip et al,
2010). Raptor positively regulates mTOR activity and is
thought to function as a scaffold that recruits mTORC1
substrates (Hara et al, 2002; Kim et al, 2002), whereas
PRAS40, Deptor and FKBP38 negatively regulate mTOR
activity (Bai et al, 2007; Sancak et al, 2007; Vander Haar
etal,2007;Petersonetal,2009).TheroleofmLST8inmTORC1
function is currently unclear, as the chronic loss of this protein
does not affect mTORC1 activity in vivo (Guertin et al, 2006b).
mTORC1 senses and integrates various environmental cues
andintracellularsignalstoregulatecellularprocessesinvolved
in the promotion of cell growth (Jacinto, 2008). To facilitate
interpretation of the major signaling inputs to mTORC1
described below, and to encourage the use of the SBGN
notation, we have drawn from the mTOR map a small-scale
scheme of mTORC1 signaling events using the SBGN process
diagram language (Figure 3). This simpliﬁed mTORC1 map
comprises 110 species, 77 reactions and 4 cellular compart-
ments, and highlights positive and negative regulatory signals
to mTORC1.
mTORC1 signaling is positively regulated by growth factors
through the PI3K–AKT pathway (Growth Factor/Nutrient
module in Figures 2 and 3). The binding of insulin to its cell
surface receptor leads to the recruitment and phosphorylation
of IRS-1, which promotes the recruitment and activation of
PI3K at the cell surface membrane. Active PI3K converts
phosphatidylinositol-4,5-phosphate to phosphatidylinositol-
3,4,5-phosphate (PIP3), a process antagonized by the lipid
phosphatase PTEN. When produced at the plasma membrane,
PIP3 recruits both PDK1 and AKT, resulting in the phosphory-
lation and partial activation of AKT. Whereas PDK1 phos-
phorylates AKT at Thr308, additional phosphorylation at
Ser473 by mTORC2 (see below) is necessary for optimal
activation of AKT in vitro (Sarbassov et al, 2005). mTORC1 is
thought to be activated in part by AKT through the tuberous
sclerosis complex proteins, TSC1 and TSC2. The TSC1–TSC2
complexisacriticalnegativeregulatorofmTORC1(Huangand
Manning, 2008b). Because of its central role in regulating
mTORC1, 34 species depicting extensive details about the
TSC1–TSC2 complex (post-translation modiﬁcations, interac-
tors, cellular locations) were represented in the comprehen-
sive mTOR map. In response to growth factors, TSC2 is
phosphorylated and functionally inactivated by AKT (Inoki
et al, 2002; Manning et al, 2002). ERK1/2 and RSK1/2 were
also shown to phosphorylate and inactivate TSC2 in response
to growth factors (Roux et al, 2004; Ballif et al, 2005; Ma et al,
2005), suggesting that PI3K and Ras/MAPK pathways colla-
borate to inhibit TSC1–TSC2 function in response to growth
factors. Whereas TSC2 functions as a GAP toward the small
Ras-related GTPase Rheb, TSC1 is required to stabilize TSC2
and prevent its proteasomal degradation (Huang and Man-
ning, 2008b). While the active GTP-bound form of Rheb was
shown to directly interact with mTOR to stimulate its catalytic
activity (Long et al, 2005), Rheb may also promote substrate
recognition by mTORC1 (Sancak et al, 2007; Sato et al, 2009).
Nutrients, such as amino acids, regulate mTORC1 signaling
via different mechanisms. Amino acid availability regulates
mTORC1 in a TSC2-independent but Rheb-dependent manner
(Smith et al, 2005; Gulati and Thomas, 2007), but the exact
mechanism remains poorly understood (Growth Factor/Nu-
trient module in Figures 2 and 3). Two complementary studies
have provided compelling evidence that the Rag family of
small GTPases is both necessary and sufﬁcient to transmit a
positive signal from amino acids to mTOR (Kim et al, 2008;
Sancak et al, 2008). The current model proposes that amino
acids induce the movement of mTORC1 to lysosomal
membranes, where Rag proteins reside. More precisely, a
complex encoded by the MAPKSP1, ROBLD3 and c11orf59
genes, interacts with the Rag GTPases, recruits them to
lysosomes, and was shown to be essential for mTORC1
activation (Sancak et al, 2010).
mTORC1 activity is sensitive to oxygen deprivation, and
one pathway by which this occurs involves activation of the
TSC1–TSC2 complex by REDD1, a hypoxia-inducible protein
(Hypoxia module in Figures 2 and 3l; Brugarolas et al, 2004).
Newly synthesized REDD1 was found to interact with 14–3–3
andrelieveTSC2from14–3–3-dependentrepression(DeYoung
et al, 2008). mTORC1 also senses insufﬁcient cellular energy
levelsthroughAMPK,a proteinkinase activatedin responseto
alowATP/AMPratio(Inokietal,2003)andbyLKB1-mediated
phosphorylation (Low Energy module in Figures 2 and 3;
Lizcano et al, 2004; Shaw et al, 2004). Upon energy depletion,
AMPK phosphorylates and activates TSC2, resulting in the
inhibition of mTORC1 (Inoki et al, 2003). The GSK3 may also
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phosphorylate TSC2 at Ser1337 and Ser1341 in response to
AMPK-mediated TSC2 phosphorylation (Wnt module in
Figures 2 and 3; Inoki et al, 2006). Site-speciﬁc phosphoryla-
tion of Raptor also has an important role in the activation of
mTORC1 in response to energy depletion. Indeed, low energy
status promotes Raptor phosphorylation at Ser722 and Ser792
by AMPK, thereby providing binding sites for 14–3–3, which
attenuates mTORC1 signaling (mTORC1 module in Figures 2
and 3; Gwinn et al, 2008). In contrast, insulin- and Rheb-
stimulatedmTORphosphorylatesRaptoronSer863topromote
mTORC1 signaling (Wang et al, 2009; Foster et al, 2010). The
Ras/MAPK pathway activated protein kinase RSK was also
shown to directly phosphorylate Raptor on Ser719, Ser721 and
Ser722, thereby promoting mTORC1 signaling (Carriere et al,
2008a,b). Four mTOR phosphorylation sites have been
identiﬁed so far: Ser1261, Ser2448, Ser2481 (an autophos-
phorylation site) and Thr2446 (Foster and Fingar, 2010).
While Ser1261 is the only site demonstrated to affect mTOR
activity (Acosta-Jaquez et al, 2009), phosphorylation of
Ser2481 was shown to correlate with the activation status of
mTOR (Soliman et al, 2010). Phosphorylation of Ser2448 was
originally found to be regulated by Akt (Nave et al, 1999), but
more recent studies demonstrated that S6K1 phosphorylates
this site as part of a feedback loop with unknown functions
(Chiang and Abraham, 2005; Holz and Blenis, 2005). The
phosphorylation status of PRAS40 and Deptor was also found
to affect mTORC1 signaling. Indeed, phosphorylation of
PRAS40 by both AKT (on Thr246) and mTORC1 (on Ser183,
Ser212, Ser221) and subsequent association of PRAS40 with
14–3–3 is critical for the activation of mTORC1 (Fonseca et al,
2007; Oshiro et al, 2007; Vander Haar et al, 2007; Wang et al,
2008). Upon activation, mTORC1 also directly phosphorylates
Deptor to promote its degradation, which further activates
mTORC1 signaling (Peterson et al, 2009). Although 13 speciﬁc
phosphorylation sites have been identiﬁed on Deptor (see
protein notes from the SBML-format ﬁle of the comprehensive
mTOR map), functional role for individual phosphorylated
residues have yet to be characterized. Collectively, these
reports suggest that multiple phosphorylation events on
mTORC1 componentscooperateto regulate mTORC1 signaling
in response to a wide variety of upstream signals.
Downstream targets of mTORC1 signaling
As described above, mTORC1 responds to diverse external and
intracellular signals to promote anabolic and inhibit catabolic
cellular processes (Foster and Fingar, 2010). Under favorable
conditions, mTORC1 promotes protein synthesis, cell growth
and proliferation (Ma and Blenis, 2009). Conversely, various
cellular stresses inhibit mTORC1 signaling to reduce biosyn-
thetic rates and allow initiation of macroautophagy. To review
major output responses from mTORC1, we have drawn a
reduced version of the mTOR map based on central mTOR
network components using the SBGN activity ﬂow diagram
language (Figure 4). This simpliﬁed map also highlights the
architecture of mTORC1 signaling and underscores the ﬂow of
positive and negative regulatory signals, which are brieﬂy
discussed in the last section.
mTORC1 regulates protein synthesis via phosphorylation of
both S6K1 and 4E-BP1 (Cap-dependent translation module in
Figures 2–4). Upon growth factor or nutrient stimulations,
mTORC1-mediated phosphorylation of 4E-BP1 induces its
dissociation from eIF4E, which enables assembly of the eIF4F
complex for competent translation initiation (Ma and Blenis,
2009).WhenactivatedbymTORC1,S6K1phosphorylatesboth
PDCD4 and eIF4B, resulting in activation of the eIF4A RNA
helicase, which unwinds secondary structures in the 50
untranslated region of mRNA to facilitate scanning of the
ribosome (Ma and Blenis, 2009). S6K1 also controls transla-
tion elongation by regulating the activity of eEF2K. SKAR-
mediated recruitment of activated S6K1 also increases the
translation efﬁciency of spliced mRNA during the pioneer
round oftranslation(Maand Blenis, 2009). Whileboth 4E-BP1
and S6K1 regulate protein synthesis, 4E-BP1 appears to be
mainly involved in cell proliferation, while S6K1 regulates cell
size (Dowling et al, 2010a). Recently, S6K1 and RSK were
found to phosphorylate the b-subunit of CCT (Abe et al,
2009). CCT is part of a chaperone network linked to
protein synthesis and has been shown to facilitate folding of
newly translated proteins in vivo (Protein Folding module in
Figures 2 and 4; Camasses et al, 2003; Albanese et al, 2006).
Although the functional role of S6K1-mediated phosphoryla-
tion of CCTb remains elusive, these ﬁndings suggest that
mTORC1 may have roles in optimizing folding of newly
synthesized proteins during or shortly after translation of
polypeptides.
Whilerapamycintreatment hasbeenshownmanyyearsago
to promote macroautophagy in yeast (Noda and Ohsumi,
1998), mTORC1 was recently demonstrated to regulate this
process through a protein complex composed of ULK1, ATG13
and FIP200 (Jung et al, 2009). Under nutrient-rich conditions,
mTORC1 inhibits autophagy through phosphorylation and
inactivation of ULK1/2 and ATG13 (Autophagy module in
Figures 2 and 4). Upon nutrient starvation or following
rapamycin treatment, inactivation of mTORC1 results in the
activation of ULK1/2, which promotes phosphorylation of
FIP200 and induces macroautophagy (Jung et al, 2009).
Intriguingly, FIP200 was also shown to interact with the
TSC1–TSC2 complex in response to nutrients, resulting in
increased S6K1 activity and cell growth (Growth Factor/Nu-
trient module in Figure 2; Gan et al, 2005). Taken together,
these observations raise the possibility that FIP200 binds
distinct protein complexes both upstream and downstream of
mTORC1 to regulate macroautophagy in response to nutrient
status.
Gene expression proﬁling experiments have shown that
B5% of the transcriptome was differentially expressed in
response to rapamycin-mediated mTOR inhibition (Guertin
et al, 2006a), suggesting a role for mTORC1 in regulating gene
expression. Additional studies have demonstrated that
mTORC1 controls lipid biosynthesis by activating PPAR-g and
SREBP-1, two transcription factors that control expression of
many lipogenic and adipogenic genes (Transcription module
in Figures 2 and 4) (Laplante and Sabatini, 2009). mTORC1
also targets Lipin1, which was shown to have a key role in
adipogenesis by promoting triglyceride synthesis and serving
as a coactivator of PPAR-g (Laplante and Sabatini, 2009). A
recent study also identiﬁed mTORC1 as an important regulator
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interaction of YY1 and PGC1-a (Cunningham et al, 2007), two
transcription factors that have key roles in mitochondrial
biogenesis (Mitochondrial Metabolism module in Figures 2
and 4). In the transcription module of the comprehensive
mTOR map, we have drawn several mTOR network-related
genes that were shown to be differentially expressed in
response to various stimulations. Although most regulatory
mechanisms involved in mTOR-dependent gene expression
remain to be determined, these studies highlight the important
roles of mTORC1 in regulating the transcriptome.
Regulation of mTORC2 signaling
The second mTOR complex, mTORC2, controls cell survival,
metabolism and proliferation in part by phosphorylating both
AKT and SGK1 (mTORC2 module in Figures 2 and 4; Jacinto
et al, 2006; Guertin et al, 2006b; Garcia-Martinez and Alessi,
2008). Some studies have also suggested a role for mTORC2 in
the control of cytoskeleton organization by promoting PKCa
and paxillin phosphorylation (Cytoskeleton Dynamic module
in Figures 2 and 4; Jacinto et al, 2004; Sarbassov et al, 2004).
mTORC2 is comprised of mTOR, Rictor, mSin1, mLST8, and
is often accompanied with PROTOR-1/PPR5 and Deptor
(Wullschleger et al, 2006; Bhaskar and Hay, 2007). Similar to
its role in mTORC1 signaling, Deptor negatively regulates
mTORC2 activity (Peterson et al, 2009). Deletion or knock-
down of the mTORC2 components mTOR, Rictor, mSin1 and
mLST8 has a dramatic effect on mTORC2 assembly and
activation of AKTand SGK1 (Jacinto et al, 2006; Guertin et al,
2006b). To be fully activated and stabilized, AKT requires
phosphorylation of both Ser308 and Ser473 by PDK1 and
mTORC2, respectively(Bhaskarand Hay, 2007; Oh et al, 2010).
While phosphorylation of both AKT sites is required for full
AKT activity in vitro, Ser473 phosphorylation is dispensable
for phosphorylation of most AKT substrates in vivo with the
exception of FOXO3 and PKCa (Guertin et al, 2006b). The
mechanisms leading to PDK1-mediated phosphorylation of
AKTarewell described, but the functional interaction between
mTORC2 and AKT is incompletely understood (Jacinto, 2008).
One possibility hinges on the presence of a PH-like domain in
mSIN1, which would promote the translocation of mTORC2 to
the plasma membrane much like what was found for PDK1
(Schroder et al, 2007).
In contrast to mTORC1, recent work revealed that the TSC1–
TSC2 complexpromotes mTORC2 activity (Huang et al, 2008a,
2009). Interestingly, a physical interaction between these two
complexes was identiﬁed, but the exact role for this new
interaction is not currently known. mTORC2 is also generally
described as being rapamycin insensitive, but it is now
becomingapparentthatwhileshort-term rapamycintreatment
does not inhibit mTORC2, longer treatments suppress the
assembly and function of mTORC2 through a mechanism that
may involve dephosphorylation and delocalization of Rictor
and mSin1 (Sarbassov et al, 2006; Rosner and Hengstschlager,
2008). Although we still know very little about the function
and regulation of mTORC2, the availability of competitive
ATP antagonists against mTOR will likely help deciphering
mTORC2-mediated cellular processes.
Inhibition of mTOR in drug-based cancer
therapy
InappropriateampliﬁcationofthemTORsignalingpathway,as
a result of diverse genetic lesions, is implicated in a variety
of human cancers (Shaw and Cantley, 2006). Consequently,
mTOR has emerged as a key target for the treatment of cancer.
Rapamycin has initially been shown to possess strong cytostatic
activities against a wide range of tumor cells in vitro,a n dw a s
foundtobeeffectiveatsuppressinggrowthofcancercellsinvivo
(Gibbons et al, 2009). A number of clinical trials using rapalogs
as anticancer drugs have been performed, and has led to FDA
approval in the case of renal cell carcinoma. However, the
overall efﬁcacy of rapamycin analogs as single agents for cancer
therapy did not meet expectations (Guertin and Sabatini, 2009;
Dowling et al, 2009). As highlighted in Figure 4, one notable
architectural feature of mTORC1 signaling is the possible
existence of a bow-tie structure. Typically, bow-tie networks
are composed of a highly conserved core part of the network
connected by diverse and redundant input and output subnet-
works with various feedback control loops (Csete and Doyle,
2004; Oda et al, 2005; Oda and Kitano, 2006). In this section, we
brieﬂy review key mTOR regulatory mechanisms within the
architecture of themTORnetworkand discuss their implications
in cancer therapy.
Impact of mTOR feedback and crosstalk
regulations in rapamycin-based therapy
In recent years, mTORC1 was shown to be involved in the
initiation of several negative feedback regulatory mechanisms
(Efeyan and Sabatini, 2010; Figure 4). Many of the described
feedback and crosstalk reactions have not been conﬁrmed
in vivo and may be cell and stimuli dependent. Nonetheless,
upon growth factor stimulation, mTORC1 activates S6K1,
which in turn phosphorylates IRS-1 at the plasma membrane,
and ultimately suppresses PI3K-mediated activation of AKT
(Manning, 2004; Harrington et al, 2005). Rapamycin-mediated
mTORC1 inhibition results in the attenuation of this negative
feedbackloop,leadingtoincreasedAKTactivityandactivation
of prosurvival signals, which would be a possible explanation
for the relative inefﬁcacy of rapamycin in cancer treatment
(Manning, 2004; Harrington et al, 2005). Activation of
elements in collateral pathways has been observed in the
bow-tie architecture of the TLR signaling network (Oda and
Kitano, 2006). As illustrated in Figure 4, mTORC1-mediated
S6K1 activation might engage mTORC2 in regulating collateral
signals that modulate upstream components of the main bow-
tie network. Indeed, two independent studies have recently
found a new crosstalk between the two mTOR complexes that
could also promote cell survival signaling in rapamycin-based
cancer therapy. Thus, mTORC2-dependent AKT activation in
the upper wing of the bow-tie was found to be negatively
regulated through S6K1-mediated phosphorylation of Rictor
on Thr1135 (Dibble et al, 2009; Julien et al, 2010). In addition,
inhibition of mTORC1 was found to stimulate Ras-dependent
activation of the MAPK pathway, a signaling cascade
frequently activated in human cancers (Carracedo et al,
2008). While the exact molecular mechanisms underlying this
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strate the potential beneﬁt of using combinatorial mTOR and
MEK inhibitors for the treatment of certain cancer types.
Recent studies have also shown that rapamycin, previously
thought to completely inhibit mTORC1 activity, does not
equally suppress mTORC1 signaling to its substrates (Choo
et al, 2008; Choo and Blenis, 2009; Thoreen et al, 2009). While
rapamycintreatmentcompletelyandsustainablyinhibitsS6K1
activation, it only partly and variably inhibits 4E-BP1
phosphorylation (Choo et al, 2008). Because 4E-BP1 is
critically involved in cap-dependent translation via regulation
of eIF4E, rapamycin-resistant mTORC1 signaling toward 4E-
BP1 is a plausible explanation for failed rapamycin-based
cancer therapies.
The mTOR signaling map outlined in this review provides a
picture of the intricate maze of regulatory interactions
and feedback control loops mediated by mTOR, both within
a bow-tie architecture and between components of different
pathways.
Combination therapies and second generation
of mTOR inhibitors
The implication of mTOR signaling in oncogenesis and the
interaction of mTOR with other pathway components suggests
the potential beneﬁt of combination therapy (Dancey, 2010).
Indeed, properly designed multicomponent therapies are the
ﬁrst step in controlling robustness to achieve clinical efﬁcacy
(Kitano, 2007). Efforts to combine the antitumor effects of
therapeutic agents targeting different molecular components
have been studied by several groups (Nelander et al, 2008;
Lehar et al, 2008a,b). With respect to mTOR, synergisms
between rapalogs and conventional therapeutics have already
been explored (reviewed in Abraham and Eng, 2008). The
abilityofmTORinhibitorstodownregulateHIF1andVEGFhas
made them interesting combination partners with VEGFR
inhibitors, such as Sorafenib and Sunitinib (Hudson et al,
2002; El-Hashemite et al, 2003). The feedback interaction
between MAPK and mTOR pathways also makes them
potential combination partners. MEK inhibitors, such as CI-
1040, in combination with rapalogs exhibit dose-dependent
synergismin human lungcancercell lines (Legrieret al, 2007).
Targeting mTOR/AKT and MEK/ERK pathways have shown
synergistic antigrowth phenotypes in androgen-dependent
prostate tumors in the mouse (Kinkade et al, 2008). Combina-
tion therapies with IGF-1 or MAPK2 inhibitors and rapalogs are
currentlyinvariousstagesofclinicalevaluation(Dancey,2010).
Combination therapies with an mTOR inhibitor provide a
promising avenue in eliciting synergistic efﬁcacy by exploiting
regulatoryinteractionbetweendifferentpathways,whichmight
not be possible in monotherapy. However, combination of
therapeutic agents can also lead to synergistic toxicity. Thus,
strategies for evaluation of toxicity and side effects need to be
systematically explored, and as signaling pathway interactions
are context-speciﬁc, different dosage regimen need to be
evaluated based on cancer subtypes or patient subgrouping.
While combination therapies with rapamycin or a rapalog
mayturnouttobeefﬁcaciousincontrollingderegulatedmTOR
signaling, several groups have developed small-molecule
active-site inhibitors of mTOR (reviewed in Guertin and
Sabatini, 2009; Dowling et al, 2010b). This research has been
bolstered by the fact that acute rapamycin treatment does not
inhibit mTORC2 and incompletely inhibits mTORC1 signaling
(Choo et al, 2008; Thoreen et al, 2009). Several ATP-
competitive mTOR inhibitors have been described (Torin1,
WYE-125132, PP242, KU-0063794) that inhibit mTOR irre-
spective of whether it is within mTORC1 or mTORC2 (Growth
Factor/Nutrient module in Figures 2 and 4; Feldman et al,
2009; Garcia-Martinezet al, 2009;Thoreenet al, 2009; Yu et al,
2009; Janes et al, 2010). Generally, these inhibitors are more
potent suppressors of protein synthesis and 4E-BP1 phosphory-
lation, and strongly promote autophagy. Some of these have
already been tested for their antitumor activities in various
cancersubtypes (breastcancer, glioma, lung andrenaltumors),
which generally appear to be more potent than what was found
for rapamycin (Mayer et al, 2004; Yu et al, 2009).
The comprehensive machine-readable interaction map
presented in this review will likely facilitate computational
modeling and systems-level study of mTOR pathway compo-
nents and interacting partners toward the discovery of novel
targets and therapeutic intervention strategies for cancer.
Perspectives
We foresee the comprehensive mTOR network to be a
guidance map in the study of mTOR signaling and its
regulation. Akin to a geographical map that facilitates the
navigation of new territories by explorers, the mTOR signaling
map will provide researchers with a tool to quickly and
efﬁciently maneuver through the complexity of mTOR inter-
actions in their quest for novel interactions and potential
pharmacological targets. Further, the availability of the map in
standardized formats (SBML and SBGN) renders the network
amenable to computational analyses based on various SBML
compliant tools (http://sbml.org/SBML_Software_Guide/
SBML_Software_Summary).
Our knowledge of the mTOR signaling network evolves
rapidly. Thus, a key feature to the construction of large-scale
biologicalnetworksistheabilitytoenrichtheproductwithup-
to-date information curatedfrom the latest scientiﬁc literature.
Further, it is of paramount importance to allowthis knowledge
to be available for community-wide curation and collabora-
tion—allowing researchers to not only access the information,
but also to curate the reactions and share comments on
possible scientiﬁc implications, hypotheses, in a community-
wide collaborative manner (Web 2.0). In this direction, we
have developed a platform for community-based curation and
enrichment of biological pathways called Payao (Matsuoka
et al, 2010). Payao is a community-based, collaborative web
service platform for gene regulatory and biochemical pathway
model curation, based on SBML and uses CellDesigner for
rendering the network. The Payao system (www.payaologue.
org) enables a community to work on the same models
simultaneously, insert tags as pop-up balloon to the parts of
the model, exchange comments, record the discussions and
eventually update the models accurately and concurrently.
The currentmTOR networkelucidated in this reviewas wellas
the maps in Figures 3 and 4 have been published on the Payao
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Payao10/bin/),searchformTORinthe‘SearchModels’ﬁeldto
accessthe models(a snapshot of themapon Payao is available
in Supplementary Figure S2).
We envision that the comprehensive mTOR map presented
in this review will provide researchers with access to up-to-
date and annotated mTOR knowledge base, allow for the
sharing of information through comment tags that will enrich
the network in a continuous cycle of open-ﬂow community-
collaborative framework.
Supplementary information
Supplementary information is available at the Molecular
Systems Biology website (www.nature.com/msb).
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